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Time to Apply the 3 R’s to Virus
Testing?
Rebecca Sheets, Grimalkin Partners
ECI VTVI, Albufeira, Portugal, June13, 2016

Disclaimer

• This presentation represents solely the opinions of the
speaker and does not reflect any U.S. government
policies or the opinions of the National Institutes of Health
or the Food & Drug Administration.

Context
•

3 R’s – reduce, refine, or replace the use of animals in product testing
• Lack of regulatory convergence

•

EU has directive (mandatory law) requiring that 3 R’s be applied; whenever in
vitro methods are available, in vivo tests should not be used.
• Illegal for European companies to not comply, but if they sell to US or other countries
that still require in vivo tests, they are in catch 22.
• EDQM is changing EP in consideration of data from study I will present

•

US has public law to REVIEW their regulations to see where 3 R’s could be applied,
but only policy to actually apply 3 R’s
• Despite data I will present, FDA has not changed requirements (policy is not translated
into action)
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Introduction
• Routine Tests for Adventitious Viruses
• in vivo with mortality or morbidity read-outs
• In tissue culture with CPE & HAd read-outs
• Transmission Electron Microscopy
• Specific PCRs for selected viruses
• PCR-based reverse transcriptase assay
• (infectivity for retroviruses)
• Bovine, porcine viruses (9 CFR tests in cell culture with CPE, HAd, and IFA read-outs)
• (MAP, RAP, HAP – in vivo or PCR)
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“Routine” Adventitious Virus Tests
Purpose of Work
• Provide regulators and manufacturers with information needed for
decision-making
• Such info normally comes from assay validation

• Provide baseline data to serve as basis of comparison for new

methods
• Provide protocols and viral stocks to permit “direct” comparisons by
developers of new methods
• Determine “value added” by in vivo methods in consideration of
3 R’s policy
5

“Routine” Adventitious Virus Tests
Breadth & Sensitivity
• These tests were developed for clinical diagnostics in mid-20th
century
• Initially used to detect SPECIFIC adventitious agents
• Use expanded to broad general screening assays
• Breadth/sensitivity had not been systematically assessed &
published
• Not validated in the manner currently developed assays would
be required
• No regulatory requirements to do so and costly to do
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“Routine” Adventitious Virus Tests
Implementation Phase
• The prime contractor, Advanced BioScience Laboratories,
awarded task to Charles River Labs to implement this project
• Compliant with Good Laboratory/Manufacturing Practices
• Experienced with routine adventitious agent testing
• In vivo and in vitro capabilities
• Virology expertise to prepare and characterize viral stocks required
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“Routine” Adventitious Virus Tests
Implementation Phase (2)
• Viral stocks prepared in cell culture
• Titrated in production cell line or positive control cell line
• Characterized for purity & identity

• In vivo testing
• Test at highest concentration for breadth
• If positive, sensitivity determined by titration (dilutions)

• In vitro testing
• Breadth and sensitivity assessed simultaneously
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“Routine” Adventitious Virus Tests
Results and Conclusions
The results can answer questions
such as:

• Is using two human cell lines
useful?

• Is a 14-day in vitro test sufficient or
are 28 days needed?
• Is sub-passage useful for suckling
mouse test sensitivity?
• Which is more sensitive – in vitro or
in vivo?

•

Yes, MRC-5 & HeLa had different
sensitivities, sometimes one was better,
sometimes the other

•

28 days more sensitive in some cases

•

No, for the viruses tested

•

With the exception of flu & VSV, the in
vitro tests were always more sensitive,
generally by logs, sometimes the
difference between detecting & not
9
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“Routine” Adventitious Virus Tests
Results and Conclusion
Table 4. In Vitro Limit of Detection of Research Virus Stocks
Virus

Vero
CPE

MRC-5

HA/HAD/IFa

CPE

HeLa

HA/HAD/IFa

CPE

Other

HA/HAD/IFa

CPE

HA/HAD/IFa
0.001 ID

Adenovirus 5

0.01 ID

Adenovirus 41

0.1 ID

BVDV
BoPIV-3

1.0 ID

nd b

nd

nd

nd

Echovirus 11

nd

nd

Influenza A

nd

nd

HSV-1

nd

nd

Undiluted

Measles

nd

nd

Undetected

Mumps

nd

nd

nd

nd

nd

nd

Coxsackie A16
Coxsackie B3

Rhinovirus 2

nd

nd

nd

nd

10.0 ID
100.0 ID
1,000.0 ID
100,000.0 ID

Rubella
Simian CMV
SV-40

VSV
nd
nd
nd
nd
nd
virus-infected cultures were tested for hemadsorption activity except BVDV (immunofluorescence), influenza A and rubella
(hemagglutination) and rhinovirus 2 and VSV (CPE only)
bNot done
b Detection by immunofluorescence
aAll
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“Routine” Adventitious Virus Tests
Results
in vivo

in vitro
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“Routine” Adventitious Virus Tests
Outcomes/Deliverables
• Viral stocks will be made available through the NIAID/DAIDS
Reagent Resource Support Program for AIDS Vaccine
Development
• http://www.niaid.nih.gov/topics/hivaids/research/vaccines/resources/re
agent/pages/default.aspx
• A research repository, not a regulatory authority control lab reagent
repository
• Not international reference materials, but research reagents

• Protocols for virus preparation, titration, and for in vivo and in vitro
12
test methods will also be made available
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